Kenneth Swart, Ph.D., joins Inotiv as Vice President,


WEST LAFAYETTE, Ind., May 11, 2021 (GLOBE NEWSWIRE) – Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in non-clinical and analytical drug discovery and development services, today announced that Kenneth Swart, Ph.D., has joined the company as Vice President , Bioanalytical Sciences. Dr.Swart’s arrival follows the closing of business acquisitions that expand the company’s pharmacology, immunohistochemistry and histopathology businesses, as well as the announcement of planned investments in human sciences. laboratory and solutions to help clients discover and develop new therapies.

“At a time when our clients’ assets reflect a mix of traditional oral drug candidates to gene therapies and vaccines, the injection of Dr. Swart’s experience and leadership into our regulated team of Bioanalytics, DMPK and Biology cellular and molecular aligns with recent internal investments. in our contract research solutions, ”said Dr. Michael Baim, senior vice president of bioanalytical operations. Dr Baim continued, “We believe that Dr Swart’s extensive experience in bioanalysis, biomarker discovery and development, as well as translational pharmacology and genomic medicine, is a perfect match for the discovery portion of our clientele. treatment for chronic inflammation, neurological diseases, oncology and hematology, infectious diseases, immunology and rare and neglected diseases. “

Dr Swart joins Inotiv with more than three decades of global experience supporting all aspects of clinical development, including a recent tenure at Parexel, where he led and influenced a 20-year evolution in the bioanalytical sciences and translational pharmacology, as well as developing genomics. and the arena of individualized medications. Through his bioanalytical, pharmacological and immunological contributions to the field, Dr Swart has maintained a rich tenure in the departments of bioanalytics and organic chemistry at the University of the Free State (Bloemfontein, South Africa).

“I am happy to be part of a company with multidisciplinary expertise and a dedication to providing solutions for clients who are looking for small molecules and biotherapeutic discoveries,” said Dr. Swart. “I look forward to helping the team expand these service offerings into a BPL facility.”

Dr Swart holds a doctorate. in Pharmacology and Bioanalytical Chemistry, Master of Medical Sciences in Pharmacology, Bachelor of Medical Sciences (Honors) in Pharmacology and Bachelor of Science in Chemistry and Physiology, all from the University of the Free State in South Africa. He is a fellow of the American Society of Mass Spectrometry and has served on the Board of Trustees and Scientific Editor of the Journal of Chromatographia.

About the company

Inotiv, Inc. is a leading contract research organization specializing in non-clinical and analytical drug discovery and development services. The Company is focused on developing innovative services that support its clients’ discovery and development goals for improved decision making and faster goal achievement. The company’s products aim to increase efficiency, improve data and reduce the cost of bringing new drugs to market. Visit inotivco.com for more information about the company.

This press release may contain forward-looking statements subject to risks and uncertainties, including, but not limited to, risks and uncertainties relating to changes in the market and demand for our products and services, development, marketing and the sale of products and services, technological, industrial and regulatory changes, the timing of the acquisitions and the success of their closing, integration and commercial and financial impact, the impact of the COVID-19 pandemic on the economy, demand for our services and products and operations, including actions taken by government authorities to deal with the pandemic, which may precipitate or exacerbate other risks and / or uncertainties and various other market and operational risks, including those detailed in documents filed by the Company with the United States Securities and Exchange Commission.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf789680-de46-464b-9780-eb76715f79dd


About Hector Hedgepeth

Check Also

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for …

Leave a Reply

Your email address will not be published.